Status:

COMPLETED

Dexmedetomidine Versus Propofol for Sedation During Awake Endotracheal Intubation

Lead Sponsor:

Sixth Affiliated Hospital, Sun Yat-sen University

Conditions:

Sedation

Intubation

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to compare the sedation effect of dexmedetomidine and propofol when they are both combined with midazolam and remifentanil during awake endotracheal intubation.

Detailed Description

Awake intubation is one of the best strategy guaranteed by the American Society of Anesthesiologists (ASA) guidelines for the management of patients with anticipated difficult airways. Hemodynamic sta...

Eligibility Criteria

Inclusion

  • Age 18-65 Years old;
  • scheduled for elective surgery under general anesthesia with oral tracheal intubation;
  • The American Society of Anesthesiologists(ASA) grade is I or II, and the cardiac function is 1-2;
  • Body mass index (BMI) 18-30 kg/m2.

Exclusion

  • Patients have severe cardiac diseases (cardiac function grading greater than grade 3/arrhythmia including sick sinus syndrome, atrial fibrillation, atrial flutter, atrioventricular block, frequent ventricular premature, multiple ventricular premature, ventricular premature R on T, ventricular fibrillation and ventricular flutter/acute coronary syndrome) or respiratory failure or hepatic failure or renal failure;
  • body mass index (BMI) ≥30 kg/m2 or \<18 kg/m2;
  • Patients with poor blood pressure control (receive regular antihypertensive medical treatment but still have systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg);
  • Patients with a higher risk of reflux and aspiration, such as full stomach, gastrointestinal obstruction, gastroparesis, and pregnant women;
  • Patients have schizophrenia, epilepsy, Parkinson's disease, intellectual disability, hearing impairment.;
  • Patients who take sedative and analgesic drugs for a long time;
  • Patients who are allergic to propofol, dexmedetomidine, midazolam or remifentanil
  • Patients who are expected to be difficult to intubate;
  • Patients who are participating in other clinical trials, or who refuse to sign informed consent.

Key Trial Info

Start Date :

March 5 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2021

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04753515

Start Date

March 5 2021

End Date

May 1 2021

Last Update

November 30 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

the Sixth Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China, 510655